
ZEUS: ziltivekimab cut hsCRP and IL-6 but did not reduce cardiovascular events
In the ZEUS trial, ziltivekimab reduced hsCRP and IL-6 as intended but heart attacks, strokes and CV deaths matched placebo, with more serious infections. Louis argues IL-6 is a marker of broad inflammation, which is why diet and colchicine work.
